Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Autoimmune Disorders

  Free Subscription


26.10.2026

2 Am J Kidney Dis
1 BMC Neurol
1 Brain
3 Diabetes
1 Intern Med
1 J Clin Endocrinol Metab
1 J Nephrol
2 J Neurol
1 J Pediatr
2 Kidney Int
1 Lancet
1 Lancet Neurol
4 Mult Scler
4 N Engl J Med
1 Neurol Clin Pract
5 Neurology
1 Proc Natl Acad Sci U S A
1 Thyroid


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Kidney Dis

  1. THURMAN JM, Poppelaars F
    Complement in Kidney Disease: Core Curriculum 2026.
    Am J Kidney Dis. 2026;88:781-796.
    PubMed         Abstract available

  2. BAGCHI S, Wang J, Teixeira-Pinto A, Scholes-Robertson N, et al
    Outcomes Following Kidney Failure From IgA Nephropathy Compared to Diabetic Kidney Disease and Other Glomerular Diseases.
    Am J Kidney Dis. 2026 Oct 22:S0272-6386(26)01182.
    PubMed         Abstract available


    BMC Neurol

  3. HUANG J, Li D, He R, Wei J, et al
    Efgartigimod-responsive autoimmune peripheral neuropathy with concurrent anti-GM2 IgG and anti-contactin-1 IgG antibodies: a rare case report.
    BMC Neurol. 2026;26:657.
    PubMed         Abstract available


    Brain

  4. HUNT DPJ
    Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion.
    Brain. 2026 Oct 21:awag308. doi: 10.1093.
    PubMed        


    Diabetes

  5. KONDO A, Ikeda K, Kaneko S, Harashima S, et al
    Insulin Dosing Is Associated With Cardiac Sympathetic Predominance Independent of Glycemic Profiles in Type 1 Diabetes Under Free-Living Conditions.
    Diabetes. 2026 Sep 14:db260456. doi: 10.2337/db26-0456.
    PubMed         Abstract available

  6. NICODEMO JL, Makri A, Polychronakos C
    What Proportion of Antibody-Negative Type 1 Diabetes Cases Have a Nonautoimmune Etiology? A Genetics-Based Estimate.
    Diabetes. 2026 Aug 24:db251110. doi: 10.2337/db25-1110.
    PubMed         Abstract available

  7. FLAMMER ER, Higdon LE, Sanda S, Brusko TM, et al
    Baseline Serum Metabolites as Predictors of Teplizumab Response in Individuals With Type 1 Diabetes.
    Diabetes. 2026 Aug 18:db260158. doi: 10.2337/db26-0158.
    PubMed         Abstract available


    Intern Med

  8. KUNO K, Koga Y, Takehara K, Yamaguchi K, et al
    Successful Inhaled Sargramostim Therapy for Autoimmune Pulmonary Alveolar Proteinosis in a Patient with an Intellectual Disability: A Caregiver-Assisted Approach.
    Intern Med. 2026 Oct 22. doi: 10.2169/internalmedicine.8088.
    PubMed         Abstract available


    J Clin Endocrinol Metab

  9. LATUPEIRISSA KM, Boelen A, Bruinstroop E, Hillebrand JJ, et al
    Letter to the Editor from Latupeirissa et al: "Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease".
    J Clin Endocrinol Metab. 2026 Oct 19:dgag427. doi: 10.1210.
    PubMed        


    J Nephrol

  10. CELEBI G, Sakir O, Uner M, Saglam A, et al
    Renal steatosis in the tubulointerstitial compartment in primary glomerulopathies: biopsy evidence and correlation with disease severity.
    J Nephrol. 2026;39:1470-1478.
    PubMed         Abstract available


    J Neurol

  11. BRAMOW S, Pontieri L, Heick A, Thormann A, et al
    Prediction of short-term and long-term responses to cladribine in relapsing-remitting multiple sclerosis: a Danish nationwide real-world study.
    J Neurol. 2026;273:676.
    PubMed         Abstract available

  12. BOURRE B, Guerrier O, Ayrignac X, Suchet L, et al
    DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naive patients with relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:679.
    PubMed         Abstract available


    J Pediatr

  13. BOND DM, Von Huben A, Lain S, Colagiuri R, et al
    Investigating the Impact of Juvenile Idiopathic Arthritis on Health, Costs, and Quality of Life in Australia: The IMPACT Study.
    J Pediatr. 2026;298:115246.
    PubMed         Abstract available


    Kidney Int

  14. ROVIN BH, Trimarchi H, Maes B, Perkovic V, et al
    Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy.
    Kidney Int. 2026 Oct 22:S0085-2538(26)00826-4. doi: 10.1016/j.kint.2026.
    PubMed         Abstract available

  15. CARA A, Singh RD, Berti GM, Vargas-Brochero MJF, et al
    Characterization of IgA, IgA immune complexes and complement depositions in IgA nephropathy using laser microdissection and mass spectrometry.
    Kidney Int. 2026 Oct 23:S0085-2538(26)00850-1. doi: 10.1016/j.kint.2026.
    PubMed         Abstract available


    Lancet

  16. WIENDL H, Bermel R, Airas L, Chitnis T, et al
    Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.
    Lancet. 2026 Oct 23:S0140-6736(26)02058-1. doi: 10.1016/S0140-6736(26)02058.
    PubMed         Abstract available


    Lancet Neurol

  17. JENSEN LT, Gold R, McVean G, Attfield KE, et al
    The clinical relevance of multiple sclerosis genetics: from susceptibility to disease severity and progression.
    Lancet Neurol. 2026 Oct 23:S1474-4422(26)00356.
    PubMed         Abstract available


    Mult Scler

  18. KWON S, Kim J, Chung YH, Kim B, et al
    Increased autoimmune disease burden before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis: A nationwide Korean cohort study.
    Mult Scler. 2026 Oct 17:13524585261494379. doi: 10.1177/13524585261494379.
    PubMed         Abstract available

  19. FREEDMAN DE, Oh J, Feinstein A
    Who declines neurocognitive testing? A cross-sectional study in people with multiple sclerosis.
    Mult Scler. 2026 Oct 17:13524585261491122. doi: 10.1177/13524585261491122.
    PubMed         Abstract available

  20. VALERO-HERNANDEZ E, Mathur J, Baker D, Liu IYH, et al
    Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies.
    Mult Scler. 2026 Oct 17:13524585261495351. doi: 10.1177/13524585261495351.
    PubMed         Abstract available

  21. ROTSTEIN DL, Halani S, Vadas P, Marriott JJ, et al
    Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.
    Mult Scler. 2026;32:1339-1342.
    PubMed         Abstract available


    N Engl J Med

  22. BARRATT J, Zhang H, Han SH, Suzuki Y, et al
    Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
    N Engl J Med. 2026 Oct 23. doi: 10.1056/NEJMoa2608682.
    PubMed         Abstract available

  23. RIZK DV, Barratt J, Suzuki Y, Zhang H, et al
    Sibeprenlimab in IgA Nephropathy - Final Phase 3 Trial Analysis.
    N Engl J Med. 2026 Oct 22. doi: 10.1056/NEJMoa2609127.
    PubMed         Abstract available

  24. BARRATT J, Farag YMK, Rice K, Cammett TJ, et al
    Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
    N Engl J Med. 2026 Oct 23. doi: 10.1056/NEJMoa2607544.
    PubMed         Abstract available

  25. BARRATT J, Brenner RM, Barbour SJ, Campbell KN, et al
    Atacicept in IgA Nephropathy - Phase 3 Trial Final Efficacy Analysis.
    N Engl J Med. 2026 Oct 22. doi: 10.1056/NEJMoa2610103.
    PubMed         Abstract available


    Neurol Clin Pract

  26. WILCOX DR, Mathieu EE, Weizenbaum EL, Baum ML, et al
    A Multidisciplinary Neuro-Lupus Program for the Evaluation and Management of Patients With SLE and Cognitive Concerns.
    Neurol Clin Pract. 2026;16:e200680.
    PubMed         Abstract available


    Neurology

  27. CORTESE R, Bianchi A, de Mauro A, Luchetti L, et al
    Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
    Neurology. 2026;107:e218673.
    PubMed         Abstract available

  28. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
    Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218641.
    PubMed        

  29. SHI JQ, Hong Y, Zhao HD, Jiang T, et al
    Reader Response: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2026;107:e214850.
    PubMed        

  30. SIEGLER JE, Galetta SL
    Editors' Note: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2026;107:e218759.
    PubMed        

  31. KRENN M, Wagner M, Cetin H
    Author Response: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2026;107:e214896.
    PubMed        


    Proc Natl Acad Sci U S A

  32. ELLYARD JI, Enders A
    Harnessing autoantibodies to target pathogenic plasma cells.
    Proc Natl Acad Sci U S A. 2026;123:e2631232123.
    PubMed        


    Thyroid

  33. MOON JH, Park J, Kim MJ, Kim J, et al
    Smartphone-Based Deep Learning Exophthalmometry in Thyroid Eye Disease: A Multicenter, Multiethnic Validation Study.
    Thyroid. 2026 Oct 7:10507256261495636. doi: 10.1177/10507256261495636.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum